Optimisation  	Optimisation  	 NNP	B-NP
of  	of  	 IN	I-NP
replication-selective  	replication-selective  	 JJ	I-NP
oncolytic  	oncolytic  	 JJ	I-NP
adenoviral  	adenoviral  	 JJ	I-NP
mutants  	mutants  	 NN	I-NP
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
chemotherapeutics  	chemotherapeutics  	 JJ	B-NP
Replication-selective  	Replication-selective  	 JJ	I-NP
oncolytic  	oncolytic  	 JJ	I-NP
adenoviruses  	adenoviruses  	 NNS	I-NP
are  	are  	 VBP	O
promising  	promising  	 VBG	B-NP
anti-tumour  	anti-tumour  	 JJ	I-NP
therapeutic  	therapeutic  	 JJ	I-NP
agents  	agents  	 NNS	I-NP
that  	that  	 WDT	O
have  	have  	 VBP	O
been  	been  	 VBN	O
proven  	proven  	 VBN	O
safe  	safe  	 JJ	O
in  	in  	 IN	O
hundreds  	hundreds  	 NNS	O
of  	of  	 IN	O
patients 	patients 	 NNS	O
.  	.  	 .	O
While  	While  	 IN	O
clinical  	clinical  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
was  	was  	 VBD	O
limited  	limited  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
viral  	viral  	 JJ	B-NP
mutants  	mutants  	 NNS	I-NP
alone 	alone 	 RB	O
,  	,  	 ,	O
outcomes  	outcomes  	 NNS	O
were  	were  	 VBD	O
improved  	improved  	 VBN	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
chemotherapeutics 	chemotherapeutics 	 NN	B-NP
.  	.  	 .	O
To  	To  	 TO	O
further  	further  	 JJ	O
increase  	increase  	 NN	B-NP
efficacy  	efficacy  	 NN	I-NP
of  	of  	 IN	O
viral-based  	viral-based  	 JJ	O
therapies  	therapies  	 NNS	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
necessary  	necessary  	 JJ	O
to  	to  	 TO	O
explore  	explore  	 VB	O
the  	the  	 DT	O
cellular  	cellular  	 JJ	B-NP
mechanisms  	mechanisms  	 NNS	I-NP
responsible  	responsible  	 JJ	O
for  	for  	 IN	O
enhanced  	enhanced  	 JJ	O
tumour  	tumour  	 JJ	O
elimination  	elimination  	 NN	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
cytotoxic  	cytotoxic  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
and  	and  	 CC	O
to  	to  	 TO	O
develop  	develop  	 VB	O
mutants  	mutants  	 VBN	O
with  	with  	 IN	O
higher  	higher  	 JJR	O
potency 	potency 	 NN	O
.  	.  	 .	O
To  	To  	 TO	O
this  	this  	 DT	O
end  	end  	 NN	O
we  	we  	 PRP	O
generated  	generated  	 VBD	O
a  	a  	 DT	O
set  	set  	 NN	O
of  	of  	 IN	O
novel  	novel  	 NN	B-NP
adenoviral  	adenoviral  	 NN	I-NP
mutants  	mutants  	 NN	I-NP
with  	with  	 IN	O
deletions  	deletions  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
anti-apoptotic  	anti-apoptotic  	 JJ	O
E1B19K-gene  	E1B19K-gene  	 NN	O
and  	and  	 CC	O
the  	the  	 DT	O
pRb-binding  	pRb-binding  	 JJ	O
E1ACR2-region 	E1ACR2-region 	 NN	O
.  	.  	 .	O
Mutants  	Mutants  	 NNP	B-NP
with  	with  	 IN	O
the  	the  	 DT	O
E1B19K  	E1B19K  	 NNP	O
deletion  	deletion  	 VBD	O
significantly  	significantly  	 RB	O
increased  	increased  	 VBN	O
tumour  	tumour  	 JJ	O
cell  	cell  	 NN	O
killing  	killing  	 VBG	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
cytotoxic  	cytotoxic  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
including  	including  	 VBG	I-NP
gemcitabine 	gemcitabine 	 NN	I-NP
,  	,  	 ,	O
5-fluorouracil  	5-fluorouracil  	 NN	B-NP
( 	( 	 -LRB-	O
5-FU 	5-FU 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
docetaxel  	docetaxel  	 NN	B-NP
and  	and  	 CC	O
mitoxantrone  	mitoxantrone  	 NN	B-NP
through  	through  	 IN	O
enhancement  	enhancement  	 NN	O
of  	of  	 IN	O
drug-induced  	drug-induced  	 JJ	O
apoptosis  	apoptosis  	 NN	B-NP
but  	but  	 CC	O
did  	did  	 VBD	O
not  	not  	 RB	O
sensitise  	sensitise  	 JJ	B-NP
normal  	normal  	 JJ	I-NP
cells  	cells  	 NNS	I-NP
to  	to  	 TO	O
drugs 	drugs 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
double-deleted  	double-deleted  	 JJ	O
AdDeltaDelta  	AdDeltaDelta  	 NN	B-NP
( 	( 	 -LRB-	O
DeltaE1ACR2  	DeltaE1ACR2  	 NNP	O
and  	and  	 CC	O
DeltaE1B19K 	DeltaE1B19K 	 CD	O
)  	)  	 -RRB-	O
mutant  	mutant  	 NN	B-NP
had  	had  	 VBD	O
high  	high  	 JJ	O
cell  	cell  	 NN	O
killing  	killing  	 VBG	B-NP
activity  	activity  	 NN	I-NP
in  	in  	 IN	O
prostate  	prostate  	 NN	B-NP
and  	and  	 CC	O
pancreatic  	pancreatic  	 JJ	B-NP
carcinoma  	carcinoma  	 JJ	I-NP
models 	models 	 NNS	I-NP
.  	.  	 .	O
Replication  	Replication  	 NNP	B-NP
was  	was  	 VBD	O
similar  	similar  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
parental  	parental  	 JJ	O
Ad5  	Ad5  	 NN	B-NP
and  	and  	 CC	O
DeltaCR2  	DeltaCR2  	 CD	B-NP
viruses  	viruses  	 NN	I-NP
in  	in  	 IN	O
all  	all  	 DT	O
tumour  	tumour  	 JJ	O
cells  	cells  	 NNS	O
and  	and  	 CC	O
was  	was  	 VBD	O
attenuated  	attenuated  	 VBN	O
in  	in  	 IN	O
normal  	normal  	 JJ	B-NP
cells 	cells 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
chemotherapeutics  	chemotherapeutics  	 JJ	B-NP
AdDeltaDelta  	AdDeltaDelta  	 JJ	I-NP
synergistically  	synergistically  	 JJ	I-NP
enhanced  	enhanced  	 JJ	I-NP
cell  	cell  	 NN	I-NP
death  	death  	 NN	I-NP
in  	in  	 IN	O
all  	all  	 DT	O
tested  	tested  	 JJ	O
cancer  	cancer  	 NN	B-NP
cell  	cell  	 NN	I-NP
lines  	lines  	 NNS	I-NP
and  	and  	 CC	O
in  	in  	 IN	O
prostate  	prostate  	 NN	B-NP
and  	and  	 CC	O
pancreatic  	pancreatic  	 JJ	B-NP
xenografts  	xenografts  	 NN	I-NP
in  	in  	 IN	O
vivo 	vivo 	 NN	B-NP
.  	.  	 .	O
These  	These  	 DT	O
data  	data  	 NNS	O
suggest  	suggest  	 VBP	O
that  	that  	 IN	O
the  	the  	 DT	O
AdDeltaDelta  	AdDeltaDelta  	 JJ	B-NP
mutant  	mutant  	 NN	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
candidate  	candidate  	 NN	O
for  	for  	 IN	O
targeting  	targeting  	 VBG	O
of  	of  	 IN	O
solid  	solid  	 JJ	O
tumours  	tumours  	 NNS	O
specifically  	specifically  	 RB	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
cytotoxic  	cytotoxic  	 JJ	B-NP
factors 	factors 	 NNS	I-NP
.  	.  	 .	O
Our  	Our  	 PRP$	O
findings  	findings  	 NNS	O
imply  	imply  	 VBP	O
that  	that  	 IN	O
less  	less  	 RBR	O
toxic  	toxic  	 JJ	B-NP
doses  	doses  	 NNS	I-NP
than  	than  	 IN	O
currently  	currently  	 RB	O
practised  	practised  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
clinic  	clinic  	 NN	O
could  	could  	 MD	O
efficiently  	efficiently  	 RB	O
target  	target  	 VB	O
adenocarcinomas  	adenocarcinomas  	 VBN	O
when  	when  	 WRB	O
combined  	combined  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
AdDeltaDelta  	AdDeltaDelta  	 JJ	B-NP
mutant 	mutant 	 NN	I-NP
.  	.  	 .	O
